Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Top Cited Papers
Open Access
- 15 June 2008
- journal article
- practice guideline
- Published by American Society of Hematology in Blood
- Vol. 111 (12) , 5446-5456
- https://doi.org/10.1182/blood-2007-06-093906
Abstract
Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute–sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.Keywords
This publication has 80 references indexed in Scilit:
- Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study GroupJournal of Clinical Oncology, 2007
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Autoimmune Complications of Chronic Lymphocytic LeukemiaSeminars in Oncology, 2006
- CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B‐CLL): Comparison of three approaches to analyze its expressionCytometry Part B: Clinical Cytometry, 2006
- A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analoguesLeukemia & Lymphoma, 2006
- Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood, 2004
- Evidence of a Graft-Versus-Leukemia Effect in Chronic Lymphocytic Leukemia After Reduced-Intensity Conditioning and Allogeneic Stem-Cell Transplantation: The Cooperative German Transplant Study GroupJournal of Clinical Oncology, 2003
- The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progressionBlood, 2003
- Treatment of Chronic Lymphocytic Leukemia: A Preliminary Report of Spanish (Pethema) TrialsLeukemia & Lymphoma, 1991